Skip to main content

Ciltacabtagene autoleucel

Details of the Drug
Generic Name:
Ciltacabtagene autoleucel
Drug Type:
B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy
How the Drug is Given:

Suspension for intravenous infusion

Ciltacabtagene autoleucel

Indications and Usage

Ciltacabtagene autoleucel is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.

Side effects needing medical attention

The most common nonlaboratory adverse reactions are fever, cytokine release syndrome, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections-pathogen unspecified, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia (rapid heartrate), dizziness, dyspnea (difficulty breathing), edema (Puffiness caused by excess fluid trapped in the body's tissues), viral infections, coagulopathy (bleeding disorder), constipation, and vomiting. The most common laboratory adverse reactions include thrombocytopenia, neutropenia, anemia, aminotransferase elevation and hypoalbuminemia. 

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.